Sharemaestro Newsreel

McKesson price regains footing - Forecast today - 06-08-2026

McKesson Corporation (MCK) closed higher, continuing its recovery with positive momentum after establishing a higher low. The stock remains in a short-term bullish corrective trend, trading above its 50-day Simple Moving Average, and momentum indicators show a bullish divergence. The outlook is bullish, targeting …

Canandaigua National Bank & Trust Co. Invests $1.56 Million in McKesson Corporation $MCK

Canandaigua National Bank & Trust Co. has invested $1.56 million in McKesson Corporation, purchasing 2,071 shares during the second quarter. McKesson exceeded quarterly expectations with adjusted EPS of $9.93 and revenue of $105.38 billion, and has raised its fiscal 2027 adjusted EPS guidance. The …

Cencora Raises 2026 EPS Outlook After Strong Quarter

Cencora reported strong fiscal third-quarter results, with revenue up 5.1% to $84.8 billion and adjusted diluted EPS increasing 12% to $4.48. The company subsequently raised its fiscal 2026 adjusted EPS guidance to $17.75–$17.95 and repurchased $1 billion in shares. These positive results were influenced …

Jenni Wheeler, Cardinal Health VP, Data Office, Joins CDO Magazine Global Board

Jenni Wheeler, VP of the Data Office at Cardinal Health, has been appointed to CDO Magazine's Global Board. She brings over 20 years of experience in data strategy, advanced analytics, and technology transformation, focusing on operationalizing data to fuel insights and drive business outcomes. …

Cardinal Health (NYSE: CAH) awards 58,738 performance share units to CFO

Cardinal Health (NYSE: CAH) has awarded its Chief Financial Officer, Aaron E. Alt, 58,738 performance share units, which will settle on August 15, 2026. This equity award was granted on August 4, 2026, at a price of $0.0000 per share. Following this transaction, Alt …

Cardinal Health (CAH) awards 17,230 performance units to its CIO

Cardinal Health's Chief Information Officer, Michelle D. Greene, was awarded 17,230 common shares in the form of performance share units. These units, which were granted at no cash purchase price, are set to settle on August 15, 2026. Following this award, Greene directly holds …

McKesson Kicks Off Fiscal 2027 With Solid Results Underpinned by Specialty and Margin Strength

McKesson, a leading pharmaceutical wholesaler, reported solid results for the start of fiscal 2027, driven by strong performance in its specialty segment and robust margins. The company, alongside Cardinal Health and Cencora, forms an oligopoly controlling over 90% of the U.S. drug distribution market. …

Cencora Inc (COR) (Q3 2026) Earnings Call Highlights: Strong Double-Digit Growth and Raised Guidance

Cencora Inc (COR) reported strong Q3 fiscal 2026 results, with double-digit adjusted operating income growth of 17% and EPS growth of 12%. The company raised its full-year fiscal 2026 adjusted EPS guidance, reflecting confidence in its performance and portfolio strength, particularly in its US …

McKesson Medical-Surgical to keep local HQ after spin off from parent company, rebranding as Wellverse

McKesson Medical-Surgical, currently headquartered in Henrico, plans to rebrand as Wellverse and maintain its local headquarters after spinning off from its parent company, Texas-based McKesson Corp. The medical supplies distributor, which employs about 1,000 people in the Richmond area, aims to become an independent, …

Cencora (COR) Stock Climbs As Margin Expansion Drives Profit Momentum

Cencora (COR) stock climbed 3.6% after its latest earnings report, driven by significant margin expansion despite modest revenue growth. Adjusted operating income increased by 17% and adjusted gross profit rose by 23%, largely due to the OneOncology acquisition and a richer specialty mix. This …

Is McKesson’s Revenue Growth With Falling EPS Altering The Investment Case For McKesson (MCK)?

McKesson Corporation reported increased sales but decreased net income and diluted EPS in Q1 2026, indicating margin pressures despite revenue growth. This situation raises questions about the company's long-term earnings profile and its ability to maintain profitability amidst evolving healthcare policies, even as management …

Cencora (NYSE:COR) Shares Tick Up as Fiscal Q3 Results Meet Estimates, Full-Year Guidance Adjusted

Cencora (NYSE:COR) reported fiscal third-quarter results that largely met Wall Street expectations, with revenue slightly below and adjusted EPS slightly above consensus. The company also raised the lower end of its full-year adjusted profit guidance, leading to a modest positive reaction in premarket trading. …

McKesson (MCK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

McKesson (MCK) reported Q1 2026 revenues of $105.38 billion, a 7.7% increase year-over-year, and an EPS of $9.93. Both revenue and EPS surpassed Zacks Consensus Estimates by 0.95% and 5.19% respectively. The article further details key segmental revenue and adjusted operating profit figures, highlighting …

McKesson’s (NYSE:MCK) Q2 CY2026 Sales Top Estimates

McKesson (NYSE:MCK) reported strong Q2 CY2026 results, exceeding revenue and adjusted EPS estimates with sales up 7.7% year-on-year to $105.4 billion and non-GAAP profit of $9.93 per share. The company slightly raised its full-year Adjusted EPS guidance and demonstrated satisfactory revenue growth, although its …

Cencora Inc (COR) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 73/100

Cencora Inc (COR) stock rose 3.6% today, reaching $317.22, but GuruFocus's GF Value assesses it as 8.1% overvalued at $293.51. Despite this overvaluation and a high P/E ratio compared to its historical median, the company maintains above-average fundamentals with a GF Score of 73/100 …

Strong Performance From Cencora's Specialty Assets Looks Durable and Offsets Industry Headwinds

Cencora, a major player in the pharmaceutical distribution market, is showing strong performance in its specialty assets, which is helping to counteract industry challenges. The company is one of three leading domestic wholesalers, accounting for about a third of the US drug distribution market. …

Mckesson Corp Stock (MCK) Closed Up by 5.08% on Aug 5: What Investors Need To Know

McKesson Corp (MCK) saw its stock price rise by 5.08% on August 5th, following a fiscal first-quarter earnings report that surpassed consensus expectations. The company's strong performance was driven by its U.S. Pharmaceutical segment and an upward revision of its full-year earnings guidance, especially …

McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance

McKesson Corporation announced its fiscal 2027 first quarter financial results and raised its full-year adjusted EPS guidance. The company will host an earnings conference call for investors, and further details and financial information are available on McKesson's Investor Relations website. McKesson is a diversified …

(MCK) McKesson Now Expects Fiscal 2027 Adjusted EPS Range $44.20-$45.00, vs. FactSet Est of $44.26

McKesson (MCK) has updated its fiscal year 2027 adjusted EPS outlook, now expecting a range of $44.20 to $45.00. This new guidance compares favorably against the FactSet estimate of $44.26. The revised forecast follows McKesson's strong fiscal Q1 results, which saw adjusted earnings and …

Cencora, Inc. 2026: Revenue $84.75B, EPS $3.94— 10-Q Summary

Cencora, Inc. reported strong financial results for the 2026 quarter, with revenue reaching $84.75 billion, net income at $763.52 million, and diluted EPS of $3.94. This growth was fueled by increased volume in both U.S. and International segments, particularly in specialty products and GLP-1 …

Cencora Releases Q3 2026 Financial Results

Cencora (COR) announced strong Q3 2026 financial results, with adjusted EPS of $4.48, beating analyst estimates, and revenue reaching $84.75 billion, also exceeding expectations. The company saw a 5.1% year-over-year revenue increase and provided an optimistic adjusted EPS forecast for FY 2026, ranging from …

McKesson earnings up next: Can revenue rebound after Q4 miss? By Investing.com

McKesson is set to release its fiscal first-quarter earnings, with investors closely watching for a rebound in revenue after a significant miss in the prior quarter. Analysts expect robust earnings and revenue growth, but the stock has experienced recent volatility due to concerns about …

Cencora (COR) Expands Credit Facilities And Resets Receivables Terms

Cencora (COR) has revised its credit and receivables facilities, including its multi-currency revolving credit facility and receivables securitization arrangements. These changes are significant for the company's capital structure and liquidity, especially given the current challenges in the pharmaceutical and healthcare services sector. Investors should …

Cardinal Health Inc. stock outperforms competitors on strong trading day

Cardinal Health Inc. (CAH) shares rose by 2.43% to $239.23, outperforming competitors on a mixed trading day where the Dow Jones Industrial Average gained but the S&P 500 Index declined. The company's stock closed 1.64% below its 52-week high.

Accendra Health Q2 Preview: Low Expectations Create Opportunity (NYSE:ACH)

Citigroup Adjusts Price Target on Henry Schein to $112 From $100

Citigroup has adjusted its price target for Henry Schein (HSIC) to $112, up from the previous $100. This update follows a series of other analyst adjustments for Henry Schein, which specializes in distributing healthcare products and services. The company recently reported strong Q2 2026 …

McKesson raises annual profit forecast on strong growth in specialty drug business

McKesson has raised its annual profit forecast for fiscal 2027 after outperforming first-quarter earnings estimates, driven by strong growth in its oncology and specialty drug businesses. The company now expects adjusted profit between $44.20 and $45 per share, exceeding previous projections and analyst expectations. …

McKesson (MCK) Q1 Earnings and Revenues Top Estimates

McKesson (MCK) reported strong Q1 earnings, with $9.93 per share, surpassing the Zacks Consensus Estimate of $9.44, and revenues of $105.38 billion, also beating expectations. The company's shares have risen 1.2% year-to-date, though underperforming the S&P 500. McKesson currently holds a Zacks Rank #2 …

Cencora Expands Credit Facilities to Bolster Liquidity

Cencora (COR) has expanded its revolving credit facility to $7 billion and extended its maturity to 2031, enhancing its long-term funding capabilities. Additionally, the company amended its receivables securitization facility, reducing its base size but doubling its accordion capacity to maintain flexible liquidity. These …

Cencora Q3 2026 slides: specialty strength drives 12% EPS growth

Cencora Inc. reported strong Q3 2026 earnings, with adjusted EPS growing 12% year-over-year to $4.48 and revenue increasing 5.1% to $84.8 billion, exceeding analyst expectations. The pharmaceutical distributor raised its full-year guidance, driven by robust performance in specialty pharmaceuticals and the acquisition of OneOncology. …

Barrington Research Adjusts Henry Schein PT to $104 From $97, Maintains Outperform Rating

Barrington Research has increased its price target for Henry Schein (HSIC) to $104 from $97, while reaffirming an "Outperform" rating on the stock. This adjustment comes amidst several other analyst revisions for Henry Schein, indicating ongoing analyst attention to the company's performance. The article …

Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?

Henry Schein, Inc. (HSIC) recently hit a new 52-week high of $92.18, with shares up 2.6% over the past month and 17.9% year-to-date. The company has consistently beaten earnings estimates, reporting strong EPS and revenue growth. With a Zacks Rank of #2 (Buy) and …

Cencora (COR) Surpasses Q3 Earnings Estimates

Cencora (COR) reported strong Q3 earnings of $4.48 per share, exceeding the Zacks Consensus Estimate of $4.37. Despite missing revenue estimates slightly at $84.75 billion, the company holds a Zacks Rank #2 (Buy) due to favorable estimate revisions, suggesting potential outperformance in the near …

Cencora Inc earnings beat by $0.13, revenue topped estimates

Cencora Inc (NYSE: COR) reported strong third-quarter results, surpassing analyst estimates with an EPS of $4.48 against a $4.35 expectation and revenue of $84.8 billion against an $84.36 billion consensus. The company also provided a positive FY 2026 EPS guidance of $17.75-$17.95, which is …

Cencora shares rise 3% on beating estimates, raised guidance

Cencora Inc. (NYSE:COR) reported strong third-quarter results, exceeding analyst expectations for both earnings per share and revenue. The company also raised its full-year earnings guidance, leading to a 3.37% increase in pre-market trading. This performance was attributed to a robust pharmaceutical-centric strategy and growth …

Did Cencora Inc (COR) Exceed Expectations with Q3 EPS of $3.94 o